Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

Blood

Volumn 115, Issue 9, 2010, Pages 1779-1784

  Westers, Theresia M ^a   Alhan, Canan ^a   Chamuleau, Martine E D ^a   Van Der Vorst, Maurice J D L ^a   Eeltink, Corien ^a   Ossenkoppele, Gert J ^a   Van De Loosdrecht, Arjan A ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR MARKER; BIOLOGICAL MARKER; ERYTHROPOIETIN; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; BLAST CELL; CANCER RISK; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MALE; MYELOBLAST; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT RESPONSE; BIOLOGICAL MODEL; BLOOD; BONE MARROW CELL; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BIOLOGICAL MARKERS; BONE MARROW CELLS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FLOW CYTOMETRY; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES;

EID: 77950363324     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-239749     Document Type: Article

References (30)

1. Hellström-Lindberg E, Malcovati L. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol. 2008;45(1):14-22.
2. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114(12):2393- 2400.
3. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 1996;87(10):4076-4081. (Pubitemid 26152251)
4. Hellström-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92(1):68-75.
5. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104(2):321-327.
6. Balleari E, Rossi E, Clavio M, et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol. 2006;85(3):174-180. (Pubitemid 43174272)
7. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol. 1995;89(4):831-837.
8. Hellström-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99(2):344-351. (Pubitemid 27497565)
9. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037-1046.
10. Jädersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26(21):3607-3613.
11. Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111(2):574-582.
12. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102(1):394-403. (Pubitemid 36759682)
13. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden V, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008;111(3):1067-1077.
14. Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood. 2008;112(7):2681-2686.
15. Ogata K, Nakamura K, Yokose N, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood. 2002;100(12):3887-3896. (Pubitemid 35396853)
16. Veltroni M, Sainati L, Zecca M, et al. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool? Pediatr Blood Cancer. 2009;52(3):357-363.
17. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
18. Mitelman F, ed. ISCN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
19. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31(6):727-736.
20. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. (Pubitemid 27132124)
21. Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-7603. (Pubitemid 46291823)
22. Malcovati L, Germing U, Kuendgen A, et al. Timedependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-3510. (Pubitemid 47315575)
23. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
24. van de Loosdrecht AA, Alhan C, Bene MC, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009;94:1124-1134.
25. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120(2):187-200. (Pubitemid 36194166)
26. Golshayan AR, Jin T, Maciejewski J, et al. Effi- cacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol. 2007;137(2):125-132. (Pubitemid 46474717)
27. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109(10):4586-4588. (Pubitemid 46743431)
28. Rigolin GM, Della Porta MG, Ciccone M, et al. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. Br J Haematol. 2004;126(4):501-507. (Pubitemid 39093091)
29. Loken MR, van de Loosdrecht AA, Ogata K, Orfao A, Wells DA. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res. 2008;32(1):5-17. (Pubitemid 350100844)
30. Westers TM, Alhan C, Cali C, Ossenkoppele GJ, van de Loosdrecht AA. Quantitative dynamics of flow cytometric aberrancies during treatment with erythropoietin/G-CSF are predictive for responses in low/int-1 risk myelodysplastic syndromes [abstract]. Blood. (ASH Annual Meeting Abstracts). 2008;112(11):586.